Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome (Q33396528)

26 July 2017

Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome (English)

1 reference

atypical hemolytic uremic syndrome

26 July 2017

liver transplantation

1 reference

based on heuristic

inferred from title

1 reference

B Nilsson

6

0 references

author name string

A R Koskinen

1

1 reference

26 July 2017

E Tukiainen

2

1 reference

26 July 2017

J Arola

3

1 reference

26 July 2017

A Nordin

4

1 reference

26 July 2017

H K Höckerstedt

5

1 reference

26 July 2017

H Isoniemi

7

1 reference

26 July 2017

T S Jokiranta

8

1 reference

26 July 2017

language of work or name

English

0 references

publication date

3 August 2011

1 reference

American Journal of Transplantation

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

9

1 reference

26 July 2017

1885-1895

1 reference

Atypical hemolytic-uremic syndrome

26 July 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Familial haemolytic uraemic syndrome and an MCP mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Thrombomodulin mutations in atypical hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Hemolytic uremic syndrome recurrence after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Combined kidney and liver transplantation for familial haemolytic uraemic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Attempted treatment of factor H deficiency by liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Liver-kidney transplantation to cure atypical hemolytic uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

The central role of the alternative complement pathway in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Complement-mediated ischemia-reperfusion injury: lessons learned from animal and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Metabolic Studies of the Third Component of Complement and the Glycine-Rich Beta Glycoprotein in Patients with Hypocomplementemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Complement membrane attack complex and hemodynamic changes during human orthotopic liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Eculizumab for Atypical Hemolytic–Uremic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

Thrombotic Microangiopathy After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-6143.2011.03612.X

10.1111/J.1600-6143.2011.03612.X

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference